Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Short-term Results With Faricimab After Multiple Sequential Treatment Switches Due to Resistance With Both Aflibercept and Ranibizumab in Neovascular Age-related Macular Degeneration

NCT06231121 is registered in ClinicalTrials.gov with Rigshospitalet, Denmark as lead sponsor.

NCT NCT06231121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06231121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Short-term Results With Faricimab After Multiple Sequential Treatment Switches Due to Resistance With Both Aflibercept and Ranibizumab in Neovascular Age-related Macular Degeneration
Lead sponsor
Rigshospitalet, Denmark
Phase
Observational
Overall status
Completed
Start date
December 1, 2023
Completion date
January 19, 2024
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration